How Insurance-Integrated Cannabis Can Add Value to the Sector

Shift from retail to healthcare

Today, most medical cannabis purchases still look a lot like consumer retail sales. Patients purchase with low brand loyalty and minimal clinical guidance.

In that environment, operators compete mostly on price and store number. If patients can present an insurance card and receive reimbursement for medical cannabis, their practice will begin to resemble traditional pharmacy.

This is the strategy behind the CannaLnx system, which is designed to mirror the workflow in traditional pharma by connecting physicians, dispensaries and payers.

According to Luce, insured patients are less likely to chase discounts and more likely to build ongoing relationships with specific dispensaries and staff. In this scenario, value shifts from the price of the product to the clinical service and outcome.

Over time, this supports repeatability and predictability in revenue, lower customer acquisition costs, and higher margins.

Viewed through an investment lens, operators integrating with insurers and pharmacy benefit managers (PBMs) may look less like retailers and more like healthcare platforms.

How can rescheduling affect market valuation?

With the US rescheduling medical cannabis from Schedule I to Schedule III for certain medical conditions and expectations of a full rescheduling once again, investors are considering whether federal recognition will bridge the valuation gap between volatile retail stocks and stable health care assets.

The current state of affairs has created a bifurcated market where recreational cannabis continues to navigate the complexities of Schedule I status while the medical field is increasingly professionalizing.

Luce emphasizes that the medical lane created by the April DEA order provides a unique structural advantage for platforms that facilitate reimbursement. By moving away from a cash-only, over-the-counter retail model, businesses can take advantage of employer-funded health plans and insurance rails.

Luce pointed to the billion-dollar acquisition of a medical cannabis pharmaceutical company by Pfizer (NYSE:PFE) as evidence of growing health care interest in the sector, but acknowledged hesitation.

“Once the rescheduling happens, we believe there’s going to be a moratorium, that the state laws will probably remain intact, we’ll probably see the benefit of 280E going away, meaning business expenses can be written off, but I think there’s going to be a little bit of a moratorium before pharma comes in, before the FDA comes in and the industry changes, and I think that’s probably going to last for several years,” Loos told INN.

He added: “But I believe this industry is going to grow, and medical cannabis will be able to stand on its own two feet next to traditional pharma to complement or (replace) a pharmaceutical.”

In the long term, value is likely to shift towards companies that can integrate into the existing institutional framework.

bottom line

As the field evolves, the investment opportunity may lie in who owns the rails designed to capture the data underpinning reimbursements, recurring medical demand and future revenue streams, including potential partnerships or exits from insurers, PBMs or pharma.

However, the success of this model is ultimately measured by its impact on health care systems and patient welfare.

“Reducing the total cost of care is the metric that matters because it reflects both better patient outcomes and a more sustainable health care system,” Luce said. “Medical cannabis has demonstrated therapeutic potential in over two dozen diagnostic categories with limited side effects compared to many traditional pharmaceuticals, which often require additional medications to manage secondary complications.

“Beyond treatment, I believe the medical cannabis industry has an opportunity to help move health care away from a reactive model and toward a more proactive, patient-centered approach to care.”